HEALTH OUTCOMES USING DIRECT-ACTING ANTIVIRAL DRUGS FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS AND F0-F1 LIVER FIBROSIS STAGE

María Martín López(1), Belén Hernández Muniesa(1), Ana Ontañón Nasarre(1), Aranzazu Pou Alonso(1), Nuria Herrero Muñoz(1), Mario García Gil(1)

(1)Hospital Universitario de Fuenlabrada: Fuenlabrada, Madrid, Spain

Abstract number: 4CPS-090
ATC code: J05 (Antivirals for systemic use)

Objective
To describe and analyse the effectiveness and safety profiles of DAA drugs in patients with F0-F1 fibrosis stage in a University Hospital.

Study Design
A retrospective, observational study

Results

EFFECTIVENESS
✓ 158 (95.8%) patients achieved SVR12
✓ One patient (0.6%) abandoned the treatment
✓ 3 (1.8%) completed it but were lost to medical follow-up before determining SVR12

SAFETY
✓ No patient left the treatment because of AE:
  ▪ Fatigue: 22.4%
  ▪ Cephalea: 12.7%
  ▪ Gastrointestinal adverse events: 4.8%
  ▪ Itching: 4.2%

Discussion
The high effectiveness rates and good safety profiles of DAA allow to treat F0-F1 patients, what may help to eradicate HCV infection, a public health problem.

Conclusion
Our real-world data corroborates clinical trials.